Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06121843 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

Recruiting
Registry status
Phase 1
Development phase
147
Enrollment target
19
Study locations

NCT06121843: Recruiting Phase 1 study of Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

NCT06121843 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 147 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06121843, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

RECRUITING
Registry status
Phase 1
Development phase
147 participants
Enrollment target
19
Study locations

Study Summary

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Elranatamab
  • DRUG Iberdomide
  • DRUG BMS-986393
  • DRUG Mezigdomide
  • DRUG Alnuctamab

Study Locations (19)

New York

  • Roswell Park Cancer Institute - Buffalo
  • Laura and Isaac Perlmutter Cancer Center - New York
  • Local Institution - 0009 - New York
  • Memorial Sloan Kettering Cancer Center - New York

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Mayo Clinic in Arizona - Phoenix - Phoenix

California

  • City of Hope Comprehensive Cancer Center - Duarte

Florida

  • Mayo Clinic in Florida - Jacksonville

Georgia

  • Northside Hospital - Atlanta

Minnesota

  • Mayo Clinic in Rochester, Minnesota - Rochester

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2024-02-22
Est. Completion 2028-08-01
Phase Phase 1

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

14 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06121843

The ClinicalTrials.gov registry entry for NCT06121843 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The listed sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Elranatamab is the first listed.

NCT06121843 reports 19 study locations spanning 15 distinct geographic areas - top geographies include New York, Massachusetts, Alabama.

Frequently Asked Questions

What is clinical trial NCT06121843 about?

NCT06121843 is a clinical study titled "A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma". The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

What is the current status of trial NCT06121843?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2024-02-22. Estimated completion is 2028-08-01.

What conditions does trial NCT06121843 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06121843?

The interventions under investigation include: Elranatamab (DRUG), Iberdomide (DRUG), BMS-986393 (DRUG), Mezigdomide (DRUG), Alnuctamab (DRUG).

Who is sponsoring clinical trial NCT06121843?

This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06121843 being conducted?

This trial has 19 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.